SPIRE-HR and SPIRE-FH trials of bococizumab meet primary endpoints

Two Phase III trials of Pfizer’s bococizumab, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint.

Click on this link for more information.

Guideline on good pharmacovigilance practices (GVP) - Module VI – Collection, management and submiss

Guideline on requirements for the production and control of immunological veterinary medicinal produ

What’s new in Pharmacovigilance? QPPV update (Issue 2, July 2017)